Long Pentraxin-3 Follows and Modulates Bladder Cancer Progression
Bladder tumors are a diffuse type of cancer. Long pentraxin-3 (PTX3) is a component of the innate immunity with pleiotropic functions in the regulation of immune response, tissue remodeling, and cancer progression. PTX3 may act as an oncosuppressor in different contexts, functioning as an antagonist...
Gespeichert in:
| Veröffentlicht in: | Cancers 2019-08, Vol.11 (9), p.1277 |
|---|---|
| Hauptverfasser: | , , , , , , , , , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | |
|---|---|
| container_issue | 9 |
| container_start_page | 1277 |
| container_title | Cancers |
| container_volume | 11 |
| creator | Matarazzo, Sara Melocchi, Laura Rezzola, Sara Grillo, Elisabetta Maccarinelli, Federica Giacomini, Arianna Turati, Marta Taranto, Sara Zammataro, Luca Cerasuolo, Marianna Bugatti, Mattia Vermi, William Presta, Marco Ronca, Roberto |
| description | Bladder tumors are a diffuse type of cancer. Long pentraxin-3 (PTX3) is a component of the innate immunity with pleiotropic functions in the regulation of immune response, tissue remodeling, and cancer progression. PTX3 may act as an oncosuppressor in different contexts, functioning as an antagonist of the fibroblast growth factor/fibroblast growth factor receptor (FGF/FGFR) system, rewiring the immune microenvironment, or acting through mechanisms not yet fully clarified. In this study we used biopsies and data mining to assess that PTX3 is differentially expressed during the different stages of bladder cancer (BC) progression. BC cell lines, representative of different tumor grades, and transgenic/carcinogen-induced models were used to demonstrate in vitro and in vivo that PTX3 production by tumor cells decreases along the progression from low-grade to high-grade advanced muscle invasive forms (MIBC). In vitro and in vivo data revealed for the first time that PTX3 modulation and the consequent impairment of FGF/FGR systems in BC cells have a significant impact on different biological features of BC growth, including cell proliferation, motility, metabolism, stemness, and drug resistance. PTX3 exerts an oncosuppressive effect on BC progression and may represent a potential functional biomarker in BC evolution. Moreover, FGF/FGFR blockade has an impact on drug resistance and stemness features in BC. |
| doi_str_mv | 10.3390/cancers11091277 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_pubme</sourceid><recordid>TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_6770810</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>2547515423</sourcerecordid><originalsourceid>FETCH-LOGICAL-c421t-e7ab6501222fbbded1181903e76d337e9bbc99ca085ef7687135c350e1324c693</originalsourceid><addsrcrecordid>eNpdUU1PwzAMjRCITWNnbqgSFy5l-WiS9oI0JgZIQ-wA5yhN3dGpS0ay8vHvKduYxnyxLT-_Z-shdE7wNWMZHhhtDfhACM4IlfIIdSmWNBYiS4736g7qhzDHbTBGpJCnqMNIkrad6KLhxNlZNAW78vqrsjGLxq6u3WeItC2iJ1c0tV5BiG5rXRTgo9FaM5p6N_MQQuXsGTopdR2gv8099Dq-exk9xJPn-8fRcBKbhJJVDFLngmNCKS3zvICCkJRkmIEUBWMSsjw3WWY0TjmUUqSSMG4Yx0AYTYzIWA_dbHiXTb6AwqxPrtXSVwvtv5XTlfo_sdWbmrkPJaTEKcEtwdWWwLv3BsJKLapgoK61BdcERWmacC7wWuvyADp3jbfte4ryRHLCE8pa1GCDMt6F4KHcHUOw-nVIHTjUblzs_7DD__nBfgDJuoyA</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2547515423</pqid></control><display><type>article</type><title>Long Pentraxin-3 Follows and Modulates Bladder Cancer Progression</title><source>MDPI - Multidisciplinary Digital Publishing Institute</source><source>Elektronische Zeitschriftenbibliothek - Frei zugängliche E-Journals</source><source>PubMed Central</source><source>PubMed Central Open Access</source><creator>Matarazzo, Sara ; Melocchi, Laura ; Rezzola, Sara ; Grillo, Elisabetta ; Maccarinelli, Federica ; Giacomini, Arianna ; Turati, Marta ; Taranto, Sara ; Zammataro, Luca ; Cerasuolo, Marianna ; Bugatti, Mattia ; Vermi, William ; Presta, Marco ; Ronca, Roberto</creator><creatorcontrib>Matarazzo, Sara ; Melocchi, Laura ; Rezzola, Sara ; Grillo, Elisabetta ; Maccarinelli, Federica ; Giacomini, Arianna ; Turati, Marta ; Taranto, Sara ; Zammataro, Luca ; Cerasuolo, Marianna ; Bugatti, Mattia ; Vermi, William ; Presta, Marco ; Ronca, Roberto</creatorcontrib><description>Bladder tumors are a diffuse type of cancer. Long pentraxin-3 (PTX3) is a component of the innate immunity with pleiotropic functions in the regulation of immune response, tissue remodeling, and cancer progression. PTX3 may act as an oncosuppressor in different contexts, functioning as an antagonist of the fibroblast growth factor/fibroblast growth factor receptor (FGF/FGFR) system, rewiring the immune microenvironment, or acting through mechanisms not yet fully clarified. In this study we used biopsies and data mining to assess that PTX3 is differentially expressed during the different stages of bladder cancer (BC) progression. BC cell lines, representative of different tumor grades, and transgenic/carcinogen-induced models were used to demonstrate in vitro and in vivo that PTX3 production by tumor cells decreases along the progression from low-grade to high-grade advanced muscle invasive forms (MIBC). In vitro and in vivo data revealed for the first time that PTX3 modulation and the consequent impairment of FGF/FGR systems in BC cells have a significant impact on different biological features of BC growth, including cell proliferation, motility, metabolism, stemness, and drug resistance. PTX3 exerts an oncosuppressive effect on BC progression and may represent a potential functional biomarker in BC evolution. Moreover, FGF/FGFR blockade has an impact on drug resistance and stemness features in BC.</description><identifier>ISSN: 2072-6694</identifier><identifier>EISSN: 2072-6694</identifier><identifier>DOI: 10.3390/cancers11091277</identifier><identifier>PMID: 31480336</identifier><language>eng</language><publisher>Switzerland: MDPI AG</publisher><subject>Biomarkers ; Bladder cancer ; Cancer ; Carcinogens ; Cell growth ; Cell proliferation ; Drug metabolism ; Drug resistance ; Fibroblast growth factor receptors ; Fibroblasts ; Gene expression ; Growth factors ; Immune response ; Innate immunity ; Invasiveness ; Medical prognosis ; Metabolism ; Metastasis ; Microenvironments ; Motility ; Pentraxins ; Phosphorylation ; Respiration ; Tumor cell lines ; Tumor cells ; Tumors</subject><ispartof>Cancers, 2019-08, Vol.11 (9), p.1277</ispartof><rights>2019 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License.</rights><rights>2019 by the authors. 2019</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c421t-e7ab6501222fbbded1181903e76d337e9bbc99ca085ef7687135c350e1324c693</citedby><cites>FETCH-LOGICAL-c421t-e7ab6501222fbbded1181903e76d337e9bbc99ca085ef7687135c350e1324c693</cites><orcidid>0000-0003-1193-8929 ; 0000-0002-8991-7813 ; 0000-0002-0328-4673 ; 0000-0002-4398-8376 ; 0000-0003-3083-0999 ; 0000-0001-8979-7068 ; 0000-0002-2291-2997 ; 0000-0002-8403-0607</orcidid></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC6770810/pdf/$$EPDF$$P50$$Gpubmedcentral$$Hfree_for_read</linktopdf><linktohtml>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC6770810/$$EHTML$$P50$$Gpubmedcentral$$Hfree_for_read</linktohtml><link.rule.ids>230,314,723,776,780,881,27901,27902,53766,53768</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/31480336$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Matarazzo, Sara</creatorcontrib><creatorcontrib>Melocchi, Laura</creatorcontrib><creatorcontrib>Rezzola, Sara</creatorcontrib><creatorcontrib>Grillo, Elisabetta</creatorcontrib><creatorcontrib>Maccarinelli, Federica</creatorcontrib><creatorcontrib>Giacomini, Arianna</creatorcontrib><creatorcontrib>Turati, Marta</creatorcontrib><creatorcontrib>Taranto, Sara</creatorcontrib><creatorcontrib>Zammataro, Luca</creatorcontrib><creatorcontrib>Cerasuolo, Marianna</creatorcontrib><creatorcontrib>Bugatti, Mattia</creatorcontrib><creatorcontrib>Vermi, William</creatorcontrib><creatorcontrib>Presta, Marco</creatorcontrib><creatorcontrib>Ronca, Roberto</creatorcontrib><title>Long Pentraxin-3 Follows and Modulates Bladder Cancer Progression</title><title>Cancers</title><addtitle>Cancers (Basel)</addtitle><description>Bladder tumors are a diffuse type of cancer. Long pentraxin-3 (PTX3) is a component of the innate immunity with pleiotropic functions in the regulation of immune response, tissue remodeling, and cancer progression. PTX3 may act as an oncosuppressor in different contexts, functioning as an antagonist of the fibroblast growth factor/fibroblast growth factor receptor (FGF/FGFR) system, rewiring the immune microenvironment, or acting through mechanisms not yet fully clarified. In this study we used biopsies and data mining to assess that PTX3 is differentially expressed during the different stages of bladder cancer (BC) progression. BC cell lines, representative of different tumor grades, and transgenic/carcinogen-induced models were used to demonstrate in vitro and in vivo that PTX3 production by tumor cells decreases along the progression from low-grade to high-grade advanced muscle invasive forms (MIBC). In vitro and in vivo data revealed for the first time that PTX3 modulation and the consequent impairment of FGF/FGR systems in BC cells have a significant impact on different biological features of BC growth, including cell proliferation, motility, metabolism, stemness, and drug resistance. PTX3 exerts an oncosuppressive effect on BC progression and may represent a potential functional biomarker in BC evolution. Moreover, FGF/FGFR blockade has an impact on drug resistance and stemness features in BC.</description><subject>Biomarkers</subject><subject>Bladder cancer</subject><subject>Cancer</subject><subject>Carcinogens</subject><subject>Cell growth</subject><subject>Cell proliferation</subject><subject>Drug metabolism</subject><subject>Drug resistance</subject><subject>Fibroblast growth factor receptors</subject><subject>Fibroblasts</subject><subject>Gene expression</subject><subject>Growth factors</subject><subject>Immune response</subject><subject>Innate immunity</subject><subject>Invasiveness</subject><subject>Medical prognosis</subject><subject>Metabolism</subject><subject>Metastasis</subject><subject>Microenvironments</subject><subject>Motility</subject><subject>Pentraxins</subject><subject>Phosphorylation</subject><subject>Respiration</subject><subject>Tumor cell lines</subject><subject>Tumor cells</subject><subject>Tumors</subject><issn>2072-6694</issn><issn>2072-6694</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2019</creationdate><recordtype>article</recordtype><sourceid>8G5</sourceid><sourceid>BENPR</sourceid><sourceid>GUQSH</sourceid><sourceid>M2O</sourceid><recordid>eNpdUU1PwzAMjRCITWNnbqgSFy5l-WiS9oI0JgZIQ-wA5yhN3dGpS0ay8vHvKduYxnyxLT-_Z-shdE7wNWMZHhhtDfhACM4IlfIIdSmWNBYiS4736g7qhzDHbTBGpJCnqMNIkrad6KLhxNlZNAW78vqrsjGLxq6u3WeItC2iJ1c0tV5BiG5rXRTgo9FaM5p6N_MQQuXsGTopdR2gv8099Dq-exk9xJPn-8fRcBKbhJJVDFLngmNCKS3zvICCkJRkmIEUBWMSsjw3WWY0TjmUUqSSMG4Yx0AYTYzIWA_dbHiXTb6AwqxPrtXSVwvtv5XTlfo_sdWbmrkPJaTEKcEtwdWWwLv3BsJKLapgoK61BdcERWmacC7wWuvyADp3jbfte4ryRHLCE8pa1GCDMt6F4KHcHUOw-nVIHTjUblzs_7DD__nBfgDJuoyA</recordid><startdate>20190830</startdate><enddate>20190830</enddate><creator>Matarazzo, Sara</creator><creator>Melocchi, Laura</creator><creator>Rezzola, Sara</creator><creator>Grillo, Elisabetta</creator><creator>Maccarinelli, Federica</creator><creator>Giacomini, Arianna</creator><creator>Turati, Marta</creator><creator>Taranto, Sara</creator><creator>Zammataro, Luca</creator><creator>Cerasuolo, Marianna</creator><creator>Bugatti, Mattia</creator><creator>Vermi, William</creator><creator>Presta, Marco</creator><creator>Ronca, Roberto</creator><general>MDPI AG</general><general>MDPI</general><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>3V.</scope><scope>7T5</scope><scope>7TO</scope><scope>7XB</scope><scope>8FE</scope><scope>8FH</scope><scope>8FK</scope><scope>8G5</scope><scope>ABUWG</scope><scope>AFKRA</scope><scope>AZQEC</scope><scope>BBNVY</scope><scope>BENPR</scope><scope>BHPHI</scope><scope>CCPQU</scope><scope>DWQXO</scope><scope>GNUQQ</scope><scope>GUQSH</scope><scope>H94</scope><scope>HCIFZ</scope><scope>LK8</scope><scope>M2O</scope><scope>M7P</scope><scope>MBDVC</scope><scope>PHGZM</scope><scope>PHGZT</scope><scope>PIMPY</scope><scope>PKEHL</scope><scope>PQEST</scope><scope>PQGLB</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>PRINS</scope><scope>Q9U</scope><scope>7X8</scope><scope>5PM</scope><orcidid>https://orcid.org/0000-0003-1193-8929</orcidid><orcidid>https://orcid.org/0000-0002-8991-7813</orcidid><orcidid>https://orcid.org/0000-0002-0328-4673</orcidid><orcidid>https://orcid.org/0000-0002-4398-8376</orcidid><orcidid>https://orcid.org/0000-0003-3083-0999</orcidid><orcidid>https://orcid.org/0000-0001-8979-7068</orcidid><orcidid>https://orcid.org/0000-0002-2291-2997</orcidid><orcidid>https://orcid.org/0000-0002-8403-0607</orcidid></search><sort><creationdate>20190830</creationdate><title>Long Pentraxin-3 Follows and Modulates Bladder Cancer Progression</title><author>Matarazzo, Sara ; Melocchi, Laura ; Rezzola, Sara ; Grillo, Elisabetta ; Maccarinelli, Federica ; Giacomini, Arianna ; Turati, Marta ; Taranto, Sara ; Zammataro, Luca ; Cerasuolo, Marianna ; Bugatti, Mattia ; Vermi, William ; Presta, Marco ; Ronca, Roberto</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c421t-e7ab6501222fbbded1181903e76d337e9bbc99ca085ef7687135c350e1324c693</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2019</creationdate><topic>Biomarkers</topic><topic>Bladder cancer</topic><topic>Cancer</topic><topic>Carcinogens</topic><topic>Cell growth</topic><topic>Cell proliferation</topic><topic>Drug metabolism</topic><topic>Drug resistance</topic><topic>Fibroblast growth factor receptors</topic><topic>Fibroblasts</topic><topic>Gene expression</topic><topic>Growth factors</topic><topic>Immune response</topic><topic>Innate immunity</topic><topic>Invasiveness</topic><topic>Medical prognosis</topic><topic>Metabolism</topic><topic>Metastasis</topic><topic>Microenvironments</topic><topic>Motility</topic><topic>Pentraxins</topic><topic>Phosphorylation</topic><topic>Respiration</topic><topic>Tumor cell lines</topic><topic>Tumor cells</topic><topic>Tumors</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Matarazzo, Sara</creatorcontrib><creatorcontrib>Melocchi, Laura</creatorcontrib><creatorcontrib>Rezzola, Sara</creatorcontrib><creatorcontrib>Grillo, Elisabetta</creatorcontrib><creatorcontrib>Maccarinelli, Federica</creatorcontrib><creatorcontrib>Giacomini, Arianna</creatorcontrib><creatorcontrib>Turati, Marta</creatorcontrib><creatorcontrib>Taranto, Sara</creatorcontrib><creatorcontrib>Zammataro, Luca</creatorcontrib><creatorcontrib>Cerasuolo, Marianna</creatorcontrib><creatorcontrib>Bugatti, Mattia</creatorcontrib><creatorcontrib>Vermi, William</creatorcontrib><creatorcontrib>Presta, Marco</creatorcontrib><creatorcontrib>Ronca, Roberto</creatorcontrib><collection>PubMed</collection><collection>CrossRef</collection><collection>ProQuest Central (Corporate)</collection><collection>Immunology Abstracts</collection><collection>Oncogenes and Growth Factors Abstracts</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>ProQuest SciTech Collection</collection><collection>ProQuest Natural Science Collection</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>Research Library (Alumni Edition)</collection><collection>ProQuest Central (Alumni Edition)</collection><collection>ProQuest Central UK/Ireland</collection><collection>ProQuest Central Essentials</collection><collection>Biological Science Collection</collection><collection>ProQuest Central</collection><collection>Natural Science Collection</collection><collection>ProQuest One Community College</collection><collection>ProQuest Central Korea</collection><collection>ProQuest Central Student</collection><collection>Research Library Prep</collection><collection>AIDS and Cancer Research Abstracts</collection><collection>SciTech Premium Collection</collection><collection>ProQuest Biological Science Collection</collection><collection>Research Library</collection><collection>Biological Science Database</collection><collection>Research Library (Corporate)</collection><collection>ProQuest Central (New)</collection><collection>ProQuest One Academic (New)</collection><collection>Publicly Available Content Database</collection><collection>ProQuest One Academic Middle East (New)</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Applied & Life Sciences</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>ProQuest Central China</collection><collection>ProQuest Central Basic</collection><collection>MEDLINE - Academic</collection><collection>PubMed Central (Full Participant titles)</collection><jtitle>Cancers</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Matarazzo, Sara</au><au>Melocchi, Laura</au><au>Rezzola, Sara</au><au>Grillo, Elisabetta</au><au>Maccarinelli, Federica</au><au>Giacomini, Arianna</au><au>Turati, Marta</au><au>Taranto, Sara</au><au>Zammataro, Luca</au><au>Cerasuolo, Marianna</au><au>Bugatti, Mattia</au><au>Vermi, William</au><au>Presta, Marco</au><au>Ronca, Roberto</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Long Pentraxin-3 Follows and Modulates Bladder Cancer Progression</atitle><jtitle>Cancers</jtitle><addtitle>Cancers (Basel)</addtitle><date>2019-08-30</date><risdate>2019</risdate><volume>11</volume><issue>9</issue><spage>1277</spage><pages>1277-</pages><issn>2072-6694</issn><eissn>2072-6694</eissn><abstract>Bladder tumors are a diffuse type of cancer. Long pentraxin-3 (PTX3) is a component of the innate immunity with pleiotropic functions in the regulation of immune response, tissue remodeling, and cancer progression. PTX3 may act as an oncosuppressor in different contexts, functioning as an antagonist of the fibroblast growth factor/fibroblast growth factor receptor (FGF/FGFR) system, rewiring the immune microenvironment, or acting through mechanisms not yet fully clarified. In this study we used biopsies and data mining to assess that PTX3 is differentially expressed during the different stages of bladder cancer (BC) progression. BC cell lines, representative of different tumor grades, and transgenic/carcinogen-induced models were used to demonstrate in vitro and in vivo that PTX3 production by tumor cells decreases along the progression from low-grade to high-grade advanced muscle invasive forms (MIBC). In vitro and in vivo data revealed for the first time that PTX3 modulation and the consequent impairment of FGF/FGR systems in BC cells have a significant impact on different biological features of BC growth, including cell proliferation, motility, metabolism, stemness, and drug resistance. PTX3 exerts an oncosuppressive effect on BC progression and may represent a potential functional biomarker in BC evolution. Moreover, FGF/FGFR blockade has an impact on drug resistance and stemness features in BC.</abstract><cop>Switzerland</cop><pub>MDPI AG</pub><pmid>31480336</pmid><doi>10.3390/cancers11091277</doi><orcidid>https://orcid.org/0000-0003-1193-8929</orcidid><orcidid>https://orcid.org/0000-0002-8991-7813</orcidid><orcidid>https://orcid.org/0000-0002-0328-4673</orcidid><orcidid>https://orcid.org/0000-0002-4398-8376</orcidid><orcidid>https://orcid.org/0000-0003-3083-0999</orcidid><orcidid>https://orcid.org/0000-0001-8979-7068</orcidid><orcidid>https://orcid.org/0000-0002-2291-2997</orcidid><orcidid>https://orcid.org/0000-0002-8403-0607</orcidid><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 2072-6694 |
| ispartof | Cancers, 2019-08, Vol.11 (9), p.1277 |
| issn | 2072-6694 2072-6694 |
| language | eng |
| recordid | cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_6770810 |
| source | MDPI - Multidisciplinary Digital Publishing Institute; Elektronische Zeitschriftenbibliothek - Frei zugängliche E-Journals; PubMed Central; PubMed Central Open Access |
| subjects | Biomarkers Bladder cancer Cancer Carcinogens Cell growth Cell proliferation Drug metabolism Drug resistance Fibroblast growth factor receptors Fibroblasts Gene expression Growth factors Immune response Innate immunity Invasiveness Medical prognosis Metabolism Metastasis Microenvironments Motility Pentraxins Phosphorylation Respiration Tumor cell lines Tumor cells Tumors |
| title | Long Pentraxin-3 Follows and Modulates Bladder Cancer Progression |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-02-20T22%3A16%3A18IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_pubme&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Long%20Pentraxin-3%20Follows%20and%20Modulates%20Bladder%20Cancer%20Progression&rft.jtitle=Cancers&rft.au=Matarazzo,%20Sara&rft.date=2019-08-30&rft.volume=11&rft.issue=9&rft.spage=1277&rft.pages=1277-&rft.issn=2072-6694&rft.eissn=2072-6694&rft_id=info:doi/10.3390/cancers11091277&rft_dat=%3Cproquest_pubme%3E2547515423%3C/proquest_pubme%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=2547515423&rft_id=info:pmid/31480336&rfr_iscdi=true |